DavidM.J.HoffmanMD

Oncology • Beverly Hills, CA

Tower Hematology Oncology

Join to view full profile

Dr. Hoffman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Hoffman's full profile

Already have an account?

Office
9090 Wilshire Blvd
Ste 200
Beverly Hills, CA 90211
Phone+1 310-888-8680

Fax+1 310-888-1886

Education & Training

UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 1997 - 2000
Cedars-Sinai Medical CenterResidency, Internal Medicine, 1994 - 1997
Chicago Medical School at Rosalind Franklin University of Medicine and ScienceClass of 1994

Certifications & Licensure

CA State Medical License 1995 - 2025
MI State Medical License 2001 - 2002
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification ARIA Radiation Oncology EMR, Varian Medical Systems, 2013
Super Doctor SuperDoctors.com

Clinical Trials

Safety and Efficacy of Telatinib in Combination With Keytruda in Subjects With Advanced Stomach and Gastroesophageal Junction Cancers or Hepatocellular Carcinoma Start of enrollment: 2021 Jul 28
Active, not recruiting
Phase 2

Publications & Presentations

PubMed

B-cell prolymphocytic leukemia: an enduring bona fide entity.
Miguel S Gonzalez-Mancera, Jean Lopategui, David Hoffman, Sumire Kitahara, Serhan Alkan
International Journal of Hematology. 2024-08-01
1 citations
Pharmacokinetics and immunogenicity of eftozanermin alfa in subjects with previously-treated solid tumors or hematologic malignancies: results from a phase 1 first-in-...
Carla Biesdorf, Xiaowen Guan, Satya R Siddani, David Hoffman, Nils Boehm
Cancer Chemotherapy and Pharmacology. 2024-04-01
32 citations
A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes.
Amer M Zeidan, Uma Borate, Daniel A Pollyea, Andrew M Brunner, Fernando Roncolato
American Journal of Hematology. 2023-02-01

Lectures

Prostate Cancer Update 2013
Cedars Sinai Medical Center, Los Angeles, California - 4/13/2013

Press Mentions

Safety and Efficacy of Telatinib in Combination with Keytruda in Subjects with Advanced Stomach and Gastroesophageal Junction Cancers or Hepatocellular CarcinomaMarch 15th, 2021
March Is the Month to Get to the Bottom of Colorectal CancerMarch 3rd, 2021

Professional Memberships

American Society of Clinical Oncology - ASCO
Member